MRI-Guided radiation shows promise for brain tumors in new trial

NCT ID NCT07586657

Not yet recruiting Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a new type of radiotherapy that uses daily MRI scans to precisely target brain metastases from lung cancer. The approach, called MR-guided adaptive radiotherapy, adjusts the radiation dose based on real-time tumor changes. Researchers hope it will improve local control and reduce brain damage compared to standard methods. The study enrolls 200 patients with large or complex brain metastases who have not had prior brain radiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: adaptive radiotherapy (MR-guided)
What this could lead to: If successful, this could establish a new standard for treating large or complex brain metastases, offering better tumor control and fewer side effects than current methods.
What could go wrong: This is a single-arm phase 3 study without a control group, so results may be less definitive. The treatment is time-consuming (40-60 minutes per session) and may not be suitable for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm in the brain non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASASES

More trials for these conditions

Other studies related to the condition(s) this trial covers.